- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00984178
Trial of Hematopoietic Stem Cells in Acute Myocardial Infarction (TECAM2)
February 1, 2010 updated by: TECAM Group
Randomized Trial Comparing Intracoronary Delivery of Bone Marrow-derived Stem Cells Versus Stem Cell Mobilisation With GCSF, a Combination of Both Therapies and Conventional Treatment in Patients With Reperfused Acute Myocardial Infarction
The aim of this study is to compare the effectiveness of four different strategies for preventing the ventricular postinfarction remodelling: 1) Conventional treatment for reperfunded extensive acute myocardial infarction, 2) Autologous bone marrow stem-cells intracoronary transplantation 3) mobilization of bone marrow stem-cells induced by granulocyte colony-stimulating factors (G-CSF); and 4) combined treatment (stem-cells transplantation plus mobilization with G-CSF).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This clinical study is a phase II randomized trial for patients with an acute extensive reperfunded myocardial infarction who undergo coronary artery revascularization with sirolimus coated stents.
The aim of this study is to compare the effectiveness of four different strategies for preventing the ventricular postinfarction remodelling: 1) Conventional treatment for reperfunded extensive acute myocardial infarction, 2) Autologous bone marrow stem-cells intracoronary transplantation 3) mobilization of bone marrow stem-cells induced by granulocyte colony-stimulating factors (G-CSF); and 4) combined treatment (stem-cells transplantation plus mobilization with G-CSF).
The investigational follow-up will be at 30 days, 4 and 9 months.Effectiveness of the therapies on neomyogenesis will be measured by Magnetic Resonance Imaging analysis of left ventricular size and global and regional function and the myocardial viability.The impact of the therapies on stent re-endothelialization and restenosis will be analysed by angiography and intracoronary ultrasounds at 30 days and 9 months.
The impact of the different treatments on neoangiogenesis will be measured by infarct related artery intracoronary study of the evolution of coronary flow reserve.
Also, it will be measured the haematopoietic precursors kinetic in the different treatment branches.
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Pedro L Sanchez, MD, PhD
- Phone Number: 34-915865882
- Email: pedrolsanchez@secardiologia.es
Study Contact Backup
- Name: Francisco Fernández-Aviles, MD, PhD
- Phone Number: 34-915865882
- Email: faviles@secardiologia.es
Study Locations
-
-
-
Valladolid, Spain, 47002
- Recruiting
- Hospital Universitario de Valladolid
-
Contact:
- Alberto San Roman, MD, PhD
- Phone Number: 34-665399285
- Email: asanroman@secardiologia.es
-
Principal Investigator:
- Alberto San Roman, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age between 18 and 75 years
Acute myocardial infarction with the following characteristics:
- Clinical symptoms of chest pain lasting >30 minutes, unresponsive to nitroglycerin.
- Typical myocardial enzymatical necrotic curve
- Total summed ST-segment elevation ≥ 6 mm in 12-lead electrocardiogram.
- Akynesis or hypokinesis in infarct-related artery area without contractility abnormalities in the rest of areas.
- Pharmacological, mechanical or both type reperfusions (facilitated angioplasty) with evidence of normal infarcted area epicardial flow (TIMI grade 3) in the first 24 hours after the beginning of the symptoms
- Successful repair of the infarct-related artery (residual post-stenting stenosis < 30% by visual estimation with epicardial normal flow [grade 3] in the first 24 hours after the beginning of the symptoms or lack of significant residual lesions evidence (<50% visual estimation) in infarct-related artery.
- Lack of evidence of significant lesions in the remaining coronary vessels or adequate revascularization achieved in the first 24 hours after symptoms began.
Exclusion Criteria:
- The presence of cardiogenic shock defined as sustained systolic blood pressure less than 90 mm Hg, with no response to fluids or systolic blood pressure less than 100 mm Hg with vasopressors (in absence of bradycardia)
- Suspicion or evidence of infarct mechanical complication
- History of sustained ventricular tachycardia or atrial fibrillation
- Patient with cardiac defibrillator or candidate for its potential implantation.
- Investigational drug treatment in the previous 4 weeks
- Actual or potential use of anti-neoplastic drugs
- Oncology antecedents in the last 5 years
- Previous treatment with trans myocardial laser revascularization
- Women of childbearing potential
- Severe concomitant disease modifying patient's survival during the study
- Inability to suspend thrombolytic treatment
- Active bleeding or major surgery within 2 weeks forbidding the use of heparin, abciximab or antiplatelet therapy.
- Previous malignant haematology disease (leukaemia or lymphomas) or hypercoagulability disorders (antiphospholipid syndrome, antithrombin, C-protein and S-protein or V Leiden Factor deficiency)
- Previous known renal failure (creatinine > 2.5 mg /dl)
- Any kind of stroke in the last year or whenever episode of haemorrhagic stroke.
- Major surgery pending in the next year
- Previously known vascular disease that prevents from catheterization.
- Evidence of hypersensitivity to Filgrastim, proteins derived from E. coli or any formulation component.
- Inability to give written informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Control group
standard treatment
|
|
EXPERIMENTAL: Bone marrow mononuclear progenitors
intracoronary transplantation of bone-marrow mononuclear progenitor cells
|
Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
|
EXPERIMENTAL: GCSF
progenitor cells mobilization through Granulocite- Colony Stimulating Factor treatment (G-CSF)
|
G-CSF will be administered at a dose of 10 mcg/kg/day.
The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
|
EXPERIMENTAL: GCSF plus bone marrow mononuclear cells
combined treatment (intracoronary transplantation plus cell mobilization with G-CSF).
|
Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
G-CSF will be administered at a dose of 10 mcg/kg/day.
The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change in left ventricular ejection fraction and left ventricular end-systolic volume relative to baseline measured by magnetic resonance
Time Frame: 9 months
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change in left ventricle end-dyastolyc volume, segment contractility, wall thickness and intravascular ultrasound reendothelization relative to baseline measured by magnetic resonance and other imaging techniques
Time Frame: 9 months
|
9 months
|
To determine the safety of the study procedures
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Francisco Fernandez-Aviles, MD, PhD, Hospital General Universitario Gregorio Maranon
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2005
Primary Completion (ANTICIPATED)
November 1, 2009
Study Registration Dates
First Submitted
September 24, 2009
First Submitted That Met QC Criteria
September 24, 2009
First Posted (ESTIMATE)
September 25, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
February 2, 2010
Last Update Submitted That Met QC Criteria
February 1, 2010
Last Verified
September 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2004-005149-36
- PI041078
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Reperfused Acute Myocardial Infarction
-
Polyphor Ltd.CompletedLarge Reperfused ST-Elevation Myocardial InfarctionUnited Kingdom, Austria, Germany, Hungary, Poland
-
Henry Ford Health SystemAbiomed Inc.Enrolling by invitationAcute Myocardial Infarction | Cardiogenic Shock | STEMI | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial Infarction | NSTEMI | Acute Myocardial Infarction With ST Elevation | Acute Myocardial Infarction of Right Ventricle (Disorder) | Acute Myocardial Infarction of Left VentricleUnited States
-
Jordan Collaborating Cardiology GroupCardiovascular Academy GroupTerminatedTriggers of Acute Myocardial Infarction | Time of Onset of Acute Myocardial Infarction | Long-term Prognosis After Acute Myocardial InfarctionJordan
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
Medical Center of South ArkansasWithdrawnAcute Coronary Syndrome | Acute ST Segment Elevation Myocardial InfarctionUnited States
-
Yuan's General HospitalKaohsiung Veterans General Hospital.; Sin-Lau HospitalUnknownAcute Myocardial Infarction, of Inferolateral Wall | Acute Myocardial Infarction, of Inferoposterior WallTaiwan
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Acute Coronary Syndrome | Acute Myocardial Infarction | Metabolic DisturbanceGreece
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Sheba Medical CenterCompletedNon ST Elevation Myocardial Infarction | Acute Coronary SyndromesIsrael
-
Medstar Health Research InstituteWithdrawnST-elevation Myocardial Infarction | Acute Myocardial InfarctionUnited States
Clinical Trials on Bone marrow mononuclear cells
-
Chinese PLA General HospitalUnknownLeft Ventricular Dysfunction | Chronic Myocardial Ischemia | Old Myocardial InfarctionChina
-
AldagenCompletedPeripheral Arterial Disease | Peripheral Vascular Disease | Critical Limb IschemiaUnited States
-
TotipotentSC Scientific Product Pvt. Ltd.Thermogenesis Corp.CompletedCritical Limb IschemiaIndia
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompletedChronic Myocardial IschemiaSpain
-
IRCCS San RaffaeleSuspended
-
Vinmec Healthcare SystemCompleted
-
The University of Texas Health Science Center,...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedIschemic StrokeUnited States
-
Hebei Medical UniversityUnknownDiabetes | Lower Limb IschemiaChina